SCHEMBL430996

SCHEMBL430996

Cc1cn(-c2ncc(C=O)s2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 4/20 0.46
MAPT P10636 1/20 0.41
CYP2E1 P05181 1/20 0.38
CYP2A6 P11509 1/20 0.38
KDM4E B2RXH2 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP19A1 P11511 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NR2E1 Q9Y466 1/20 0.31
EGLN2 Q96KS0 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24135108 0.80 KCNJ1 (0.44) KCNJ1TDP1ALDH1A1MAPTKDM4E
SCHEMBL12402380 0.77 CYP2E1 (0.41) CYP2E1CYP2A6PDE3BPDE3ACYP1A2
SCHEMBL20575494 0.76 KCNJ1 (0.44) KCNJ1TDP1ALDH1A1MAPT
SCHEMBL23794772 0.74 HCAR2 (0.50) CYP2E1CYP2A6KDM4EPDE4APDE4B
SCHEMBL10312547 0.70 KCNJ1 (0.51) KCNJ1TDP1ALDH1A1MAPTCYP2A6
SCHEMBL23794732 0.69 CDC7 (0.48) ALDH1A1MAPTKDM4ECYP1A2CYP3A4
SCHEMBL20168381 0.69 CYP2A6 (0.40) KCNJ1ALDH1A1CYP2E1CYP2A6PDE3B
SCHEMBL550353 0.68
SCHEMBL8037303 0.67 CYP1A2 (0.53) KCNJ1ALDH1A1CYP2E1CYP2A6KDM4E
SCHEMBL8738123 0.67 KCNJ1 (0.47) KCNJ1CYP2E1CYP2A6KDM4EPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575150-B2 Triazole derivatives for treatment of Alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2013-11-05 US disclosed
US-20120022044-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2012-01-26 US disclosed
EP-2378879-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE Merck Sharp & Dohme Corp. (US) 2011-10-26 EP disclosed
WO-2010071741-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME CORP. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022044-A1 TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MAPT, BACE1, APP KCNJ1 875/4885TDP1 1237/4885ALDH1A1 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.